Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Digital Health

Digital Health

Evaluate

April 14, 2023

Sofinnova goes digital

The promise of fast timelines and early revenues lure a new investor into digital medicine.

Thumbnail
August 30, 2022

ESC 2022 – Preventicus gets halfway there

Improving atrial fibrillation diagnosis is one thing; improving outcomes another.

Article image
Vantage logo
August 18, 2022

Better Therapeutics banks on data and partnerships

But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.

Article image
Vantage logo
August 12, 2022

Trad device start-ups catch the cash

Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.

Article image
Vantage logo
June 15, 2022

To back, or back away from, digital health?

Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.

Article image
Vantage logo
May 20, 2022

Pfizer and its Sidekick snare a new approval

Article image
Vantage logo
April 08, 2022

Viz AI passes the $1bn valuation mark

Article image
Vantage logo
January 26, 2022

Akili plays the Spac game for $1bn

But, judging by similar transactions, the valuation might not stay that high for long.

Article image
Vantage logo
January 24, 2022

Watson, Watsoff

Article image
Vantage logo
October 22, 2021

23andme's latest deal leaves a sour taste

Article image
Vantage logo
September 29, 2021

Akili and Shionogi find the clinical game hard to play

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up